Comparison of Biometry Measurements Using Standard Partial Coherence Interferometry versus New Scheimpflug Tomography with Integrated Axial Length Capability.

Purpose: To compare biometry measurements obtained by a partial interferometer biometer (IOLMaster 500) to the new Scheimpflug tomography with an integrated axial length biometer module (Pentacam AXL).

Patients And Methods: Cataract patients who underwent biometric measurements with the IOL Master 500 and the Pentacam AXL from July to November 2017 were enrolled in this study. Comparisons were performed for axial length (AL), keratometry (K), and anterior chamber depth (ACD).

Objective evaluation of vision quality in pseudophakic patients with posterior capsular opacification using double-pass retinal imaging.

Purpose: The purpose of this study was to objectively assess the optical vision quality of patients before and after Nd:YAG capsulotomy for posterior capsular opacification using a double-pass retinal imaging system.

Methods: We retrospectively analyzed the data from 26 pseudophakic eyes with posterior capsular opacification that underwent Nd:YAG capsulotomy. The objective scatter indices, modulation transfer function cutoff frequencies, Strehl ratios, and logMAR corrected distance visual acuities were assessed before and after YAG capsulotomy with a double-pass retinal imaging system (OQAS II, Visiometrics, Spain).

Emerging Technology in Refractive Cataract Surgery.

Technology in cataract surgery is constantly evolving to meet the goals of both surgeons and patients. Recent major advances in refractive cataract surgery include innovations in preoperative and intraoperative diagnostics, femtosecond laser-assisted cataract surgery (FLACS), and a new generation of intraocular lenses (IOLs). This paper presents the latest technologies in each of these major categories and discusses how these contributions serve to improve cataract surgery outcomes in a safe, effective, and predictable manner.

Corneal cross-linking: engineering a predictable model.

Corneal collagen cross-linking (CXL) with riboflavin and ultraviolet-A (UVA) light has become a viable treatment for keratoconus. In cases in which corneal transplant may have previously been a patient's primary treatment option, the results of CXL have varied from decreased progression of the disease to marked regression characterized by improvement in visual acuity. In addition, changes to the original protocol have been tested that include leaving the epithelium intact and increasing the UVA intensity while decreasing the exposure time.